Study objective was to assess the effectiveness of antiviral therapy for chronic hepatitis C in HIV patients. For this, a group of 60 HIV patients who were treated with PEGylated interferon and ribavirin for chronic hepatitis C was evaluated retrospectively. The patients were examined using general clinical, biochemical, serological, molecular-biological, and genotyping approaches. Treatment results were assessed monthly based on clinical data, viral load, and ALT activity. Sustained virologic response criteria were applied after the completion of the treatment to determine its effect. The results suggest that the use of PEGylated interferon and ribavirin is currently an affordable approach to HIV patient curing of chronic hepatitis C. The independent factors that influence the achievement of sustained virologic response include younger age, increased ALT, and lower replication activities of HCV and HIV.